Clinical Trial Update: Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SGN-15 in hormone-refractory prostate cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• SGN-15

Snippet

Sponsor: Seagen Inc. | Conditions: Prostatic Neoplasms | Phase 2 | Status: COMPLETED